Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 75 years (male or female)
• People with a laboratory-confirmed diagnosis of a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC), at stages IB, II, IIIA, or IIIB (N2)
• People who have not received any treatment for their lung cancer before surgery
• People whose cancer can be removed with surgery, and whose lung function is strong enough to tolerate that surgery
• People whose cancer does not have specific gene changes known as EGFR mutations or ALK translocation
• People who have at least one measurable tumour, as assessed by standard imaging criteria
• People with a good general level of physical functioning (rated 0 or 1 on a standard medical scale, meaning fully active or able to carry out light activity)
• People with adequate organ function confirmed through screening tests

Who may not be able to join:

• People whose lung cancer is confirmed to be small cell lung cancer, or certain other tumour types including neuroendocrine carcinoma, sarcoma, salivary gland tumour, mesenchymal tumour, or a mixed type with mainly squamous cell features
• People whose tumour has grown into nearby important structures and is causing symptoms or requiring medical treatment
• People with a type of tumour located at the top of the lung called a Pancoast tumour
• People who have a cancerous tumour nodule in the opposite lung
• People with known or suspected cancer spread to the brain or other distant parts of the body
• People who have used Chinese herbal medicines, traditional Chinese medicinal products with anti-tumour properties, or immune-modifying drugs within 2 weeks before the first study treatment
• People who need ongoing steroid treatment throughout the body, or who have received other immune-suppressing therapy within 7 days before the first study treatment
• People who have had a blood clot in an artery within the 6 months before the first study treatment
• People who have had a blood clot in a deep vein, a clot in the lungs, or another serious blood clot in a vein within 3 months before the first study treatment
• People with a history of lung inflammation (pneumonitis) that required steroid treatment, or significant lung disease (or suspected lung disease seen on imaging during screening)
• People with active or uncontrolled medical conditions (confirm with trial site)
• People with a history of immune deficiency disease
• People who have had an active autoimmune disease requiring treatment throughout the body at any point in the 2 years before the first study treatment

Important: Always verify eligibility with the trial site directly before applying.